OvaScience Inc. (NASDAQ:OVAS) traded down 6.6% during mid-day trading on Wednesday . The company traded as low as $1.27 and last traded at $1.28. 649,837 shares were traded during mid-day trading, an increase of 66% from the average session volume of 391,859 shares. The stock had previously closed at $1.37.

A number of equities research analysts have recently issued reports on the company. Zacks Investment Research upgraded OvaScience from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of OvaScience in a research report on Thursday, August 3rd. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of OvaScience in a research report on Friday, May 12th.

The company’s market capitalization is $46.39 million. The stock’s 50 day moving average price is $1.49 and its 200-day moving average price is $1.49.

OvaScience (NASDAQ:OVAS) last released its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.45) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.02. The firm had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.09 million. OvaScience had a negative net margin of 16,132.47% and a negative return on equity of 69.13%. OvaScience’s revenue for the quarter was down 55.6% on a year-over-year basis. During the same period in the previous year, the company earned ($0.62) EPS. Equities research analysts predict that OvaScience Inc. will post ($1.67) EPS for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in OVAS. EcoR1 Capital LLC purchased a new stake in OvaScience in the 1st quarter worth approximately $6,568,000. Legal & General Group Plc grew its stake in OvaScience by 4,654.1% in the 2nd quarter. Legal & General Group Plc now owns 458,822 shares of the biotechnology company’s stock worth $713,000 after acquiring an additional 449,171 shares during the period. Sabby Management LLC grew its stake in OvaScience by 774.7% in the 1st quarter. Sabby Management LLC now owns 423,775 shares of the biotechnology company’s stock worth $792,000 after acquiring an additional 375,325 shares during the period. Broadfin Capital LLC purchased a new stake in OvaScience in the 2nd quarter worth approximately $429,000. Finally, GMT Capital Corp grew its stake in OvaScience by 43.6% in the 1st quarter. GMT Capital Corp now owns 757,114 shares of the biotechnology company’s stock worth $1,416,000 after acquiring an additional 229,719 shares during the period. 56.28% of the stock is owned by hedge funds and other institutional investors.

WARNING: “OvaScience Inc. (OVAS) Trading Down 6.6%” was posted by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.dailypolitical.com/2017/09/08/ovascience-inc-ovas-trading-down-6-6.html.

OvaScience Company Profile

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.